Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression

Somerset Pharmaceuticals300 enrolled

Overview

Objective of this 16-week, open-label study is to assess the safety and tolerability of once daily application of three doses of STS during continuous dosing in the treatment of elderly subjects with major depression. Subjects will have study visits (clinic visits) at beginning of study (baseline) and study weeks 1, 3, 5, 8, 12, and 16.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

300

Conditions

Major Depression

Interventions

Selegiline Transdermal SystemDRUG

Eligibility

Sex: ALLMin age: 65 Years

Medical Language ↔ Plain English

* Men/Women in good health 65 years or older * Ability to read, understand and sign study informed consent * Major depression- mild to severe based on rating scale

Locations (15)

Mohammed Bari, M.D.

Chula Vista, California, United States

Charles Meredith, M.D.

San Diego, California, United States

Daniel Zimbroff, M.D.

Upland, California, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.